Activation of placenta-specific transcription factor distal-less homeobox 5 predicts clinical outcome in primary lung cancer patients

Clinical Cancer Research

Volumn 14, Issue 8, 2008, Pages 2363-2370

  Kato, Tatsuya ^a,b   Sato, Nagato ^a   Takano, Atsushi ^a   Miyamoto, Masaki ^b   Nishimura, Hitoshi ^c   Tsuchiya, Eiju ^d   Kondo, Satoshi ^b   Nakamura, Yusuke ^a   Daigo, Yataro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; TRANSCRIPTION FACTOR DLX5;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; EMBRYO DEVELOPMENT; FEMALE; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NORTHERN BLOTTING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; TISSUE MICROARRAY; TUMOR VOLUME;

CELL LINE, TUMOR; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 42249095218     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1523     Document Type: Article

References (44)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Sozzi G. Molecular biology of lung cancer. Eur J Cancer 2001;37 Suppl 7:S63-73.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
4. Kelly K, Crowley J, Bunn PA, Jr., et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatinin the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
7. Kikuchi T, Daigo Y, Katagiri T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003;22:2192-205.
8. Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet 2004;13:3029-43.
9. Kikuchi T, Daigo Y, Ishikawa N, et al. Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol 2006;28:799-805.
10. Taniwaki M, Daigo Y, Ishikawa N, et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol 2006;29:567-75.
11. Kakiuchi S, Daigo Y, Tsunoda T, et al. Genome-wide analysis of organ-preferential metastasis of human small cell lung cancer in mice. Mol Cancer Res 2003;1:485-99.
12. Suzuki C, Daigo Y, Kikuchi T, Katagiri T, Nakamura Y. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res 2003;63:7038-41.
13. Ishikawa N, Daigo Y, Yasui W, et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004;10:8363-70.
14. Kato T, Daigo Y, Hayama S, et al. A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis. Cancer Res 2005;65:5638-46.
15. Furukawa C, Daigo Y, Ishikawa N, et al. Plakophilin 3 oncogene as prognostic marker and therapeutic target for lung cancer. Cancer Res 2005;65:7102-10.
16. Ishikawa N, Daigo Y, Takano A, et al. Increases of amphiregulin and transforming growth factor-α in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005;65:9176-84.
17. Suzuki C, Daigo Y, Ishikawa N, et al. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. Cancer Res 2005;65:11314-25.
18. Ishikawa N, Daigo Y, Takano A, et al. Characterization of SEZ6L2 cell-surface protein as a novel prognostic marker for lung cancer. Cancer Sci 2006;97:737-45.
19. Takahashi K, Furukawa C, Takano A, et al. The neuromedin u-growth hormone secretagogue receptor 1b/ neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. Cancer Res 2006;66:9408-19.
20. Hayama S, Daigo Y, Kato T, et al. Activation of CDCA1-2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 2006;66:10339-48.
21. Kato T, Hayama S, Yamabuki T, et al. Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer. Clin Cancer Res 2007;13:434-42.
22. Suzuki C, Takahashi K, Hayama S, et al. Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer. Mol Cancer Ther 2007;6:542-51.
23. Yamabuki T, Takano A, Hayama S, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007;67:2517-25.
24. Hayama S, Daigo Y, Yamabuki T, et al. Phosphorylation and activation of CDCA8 by AURKB plays a significant role in human lung carcinogenesis. Cancer Res 2007;67:4113-22.
25. Kato T, Sato N, Hayama S, et al. Activation of holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res 2007;67:8544-53.
26. Taniwaki M, Takano A, Ishikawa N, et al. Activation of KIF4A as a prognostic biomarker and therapeutic target for lung cancer. Clin Cancer Res 2007;13:6624-31.
27. Ishikawa N, Takano A, Yasui W, et al. Cancer-Testis Antigen, LY6K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007;67:11601-11.
28. Mano Y, Takahashi K, Ishikawa N, et al. Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer. Cancer Sci 2007;98:1902-13.
29. Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 2007;98:1803-8.
30. Liu JK, Ghattas I, Liu S, Chen S, Rubenstein JL. Dlx genes encode DNA-binding proteins that are expressed in an overlapping and sequential pattern during basal ganglia differentiation. Dev Dyn 1997;210:498-512.
31. Downing JR, Shannon KM. Acute leukemia: a pediatric perspective. Cancer Cell 2002;2:437-45.
32. Robledo RF, Rajan L, Li X, Lufkin T. The Dlx5 and Dlx6 homeobox genes are essential for craniofacial, axial, and appendicular skeletal development. Genes Dev 2002;16:1089-101.
33. Chin SF, Daigo Y, Huang HE, et al. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol Pathol 2003;56:275-9.
34. Callagy G, Cattaneo E, Daigo Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 2003;12:27-34.
35. Callagy G, Pharoah P, Chin SF, et al. Identification and validation of prognostic markers in breast cancer with the complementary use of array-CGH and tissue microarrays. JPathol 2005;205:388-96.
36. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714-27.
37. Simeone A, Acampora D, Pannese M, et al. Cloning and characterization of two members of the vertebrate Dlx gene family. Proc Natl Acad Sci U S A 1994;91:2250-4.
38. McGuinness T, Porteus MH, Smiga S, et al. Sequence, organization, and transcription of the Dlx-1 and Dlx-2 locus. Genomics 1996;35:473-85.
39. Nakamura S, Stock DW, Wydner KL, et al. Genomic analysis of a new mammalian distal-less gene: Dlx7. Genomics 1996;38:314-24.
40. Merlo GR, Paleari L, Mantero S, et al. Mouse model of split hand/foot malformation type I. Genesis 2002;33:97-101.
41. Lee JY, Lee YM, Kim MJ, et al. Methylation of the mouse Dlx5 and Osx gene promoters regulates cell type-specific gene expression. Mol Cells 2006;22:182-8.
42. Ryoo HM, Hoffmann HM, Beumer T, et al. Stage-specific expression of Dlx-5 during osteoblast differentiation: involvement in regulation of osteocalcin gene expression. Mol Endocrinol 1997;11:1681-94.
43. Ota T, Choi KB, Gilks CB, Leung PC, Auersperg N. Cell type- and stage-specific changes in HOXA7 protein expression in human ovarian folliculogenesis: possible role of GDF-9. Differentiation 2006;74:1-10.
44. Haller K, Rambaldi I, Daniels E, Featherstone M. Subcellular localization of multiple PREP2 isoforms is regulated by actin, tubulin, and nuclear export. J Biol Chem 2004;279:49384-94.